Medy-Tox Inc (086900) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.041x

Based on the latest financial reports, Medy-Tox Inc (086900) has a cash flow conversion efficiency ratio of 0.041x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩19.03 Billion ≈ $12.90 Million USD) by net assets (₩467.65 Billion ≈ $316.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 086900 market cap overview for the company's overall valuation and market capitalisation.

Medy-Tox Inc - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Medy-Tox Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Medy-Tox Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Medy-Tox Inc ranked by their cash flow conversion efficiency. Explore 086900 cash to earnings ratio to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Qingdao Hi-Tech Moulds & Plastics Technology Co. Ltd. SHE:301022	0.051x
Interarch Building Products Limited NSE:INTERARCH	0.048x
Companhia Brasileira de Distribuição SA:PCAR3	0.222x
Wuhan Citms Technology Co Ltd SHG:688038	-0.054x
XiAn Global Printing Co Ltd SHE:002799	0.011x
Fujian Yuanxiang New Materials Co. Ltd. A SHE:301300	N/A
Rana Gruber AS OL:RANA	0.544x
AIM Industrial Growth Freehold and Leasehold Real Estate Investment Trust BK:AIMIRT	0.013x

Annual Cash Flow Conversion Efficiency for Medy-Tox Inc (2013–2024)

The table below shows the annual cash flow conversion efficiency of Medy-Tox Inc from 2013 to 2024. View Medy-Tox Inc stock quote for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩470.78 Billion ≈ $319.04 Million	₩36.89 Billion ≈ $25.00 Million	0.078x	+174.98%
2023-12-31	₩474.48 Billion ≈ $321.55 Million	₩13.52 Billion ≈ $9.16 Million	0.028x	-53.44%
2022-12-31	₩428.04 Billion ≈ $290.08 Million	₩26.20 Billion ≈ $17.75 Million	0.061x	+22.47%
2021-12-31	₩399.48 Billion ≈ $270.72 Million	₩19.97 Billion ≈ $13.53 Million	0.050x	-56.80%
2020-12-31	₩241.40 Billion ≈ $163.59 Million	₩27.93 Billion ≈ $18.93 Million	0.116x	-11.05%
2019-12-31	₩259.15 Billion ≈ $175.62 Million	₩33.70 Billion ≈ $22.84 Million	0.130x	-40.35%
2018-12-31	₩252.59 Billion ≈ $171.17 Million	₩55.07 Billion ≈ $37.32 Million	0.218x	-26.10%
2017-12-31	₩191.65 Billion ≈ $129.88 Million	₩56.55 Billion ≈ $38.32 Million	0.295x	-19.46%
2016-12-31	₩147.68 Billion ≈ $100.08 Million	₩54.10 Billion ≈ $36.66 Million	0.366x	+85.86%
2015-12-31	₩113.48 Billion ≈ $76.91 Million	₩22.37 Billion ≈ $15.16 Million	0.197x	-84.74%
2014-12-31	₩81.59 Billion ≈ $55.29 Million	₩105.38 Billion ≈ $71.41 Million	1.292x	+372.27%
2013-12-31	₩60.68 Billion ≈ $41.13 Million	₩16.60 Billion ≈ $11.25 Million	0.273x	--

About Medy-Tox Inc

KQ:086900 Korea Biotechnology

Market Cap

$306.29 Million

₩451.96 Billion KRW

Market Cap Rank

#14783 Global

#473 in Korea

Share Price

₩68700.00

Change (1 day)

-0.15%

52-Week Range

₩66900.00 - ₩138600.00

All Time High

₩671543.08